DEFA14A: NeueHealth to Be Acquired by NEA in $1.3 Billion Deal, Offering 70% Premium

NeueHealth, Inc. has entered into a definitive agreement to be acquired by an affiliate of New Enterprise Associates (NEA) at $7.33 per share in cash, representing a 70% premium over the closing price on December 23, 2024.

Summary

• NeueHealth, Inc. will be acquired by an affiliate of New Enterprise Associates (NEA) in a transaction valuing the company at approximately $1.3 billion.
• Shareholders of NeueHealth common stock will receive $7.33 per share in cash, representing a premium of approximately 70% over the closing price on December 23, 2024.
• Certain stockholders, including NEA and 12 existing investors, will roll over their equity into the privately held company.
• The executive leadership team will continue in their roles and roll over 100% of their equity interests.
• The transaction is subject to stockholder and regulatory approvals and is expected to close after the go-shop period.
• NEA intends to finance the transaction with fully committed equity financing.
• Lincoln International, LLC is acting as financial advisor to the Special Committee.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant premium offered to stockholders, the continued leadership of the executive team, and the backing of a reputable firm like NEA. The transaction is presented as a strategic move to enhance NeueHealth's growth and value proposition.

Positives

• The acquisition provides a 70% premium to common stockholders.
• The company will have the flexibility and resources to continue advancing its value-driven, consumer-centric care model as a private entity.
• The existing leadership team will remain in place.
• NEA has committed equity financing for the transaction.
• The go-shop period allows for the potential of a superior proposal.

Negatives

• Upon completion of the transaction, NeueHealth's common stock will no longer be publicly traded or listed on any public market.

Risks

• The transaction may not be completed on the anticipated terms or timeframe.
• Potential litigation could be instituted against NEA, the Company, or their affiliates.
• Adverse reactions or changes to business relationships could result from the announcement, pendency, or completion of the transaction.
• The stock price may decline significantly if the transaction is not consummated.
• Restrictions during the pendency of the transaction may impact the ability to pursue certain business opportunities.
• Costs associated with the transaction may be significant.
• Events could occur that give rise to the termination of the merger agreement.
• The company's ability to continue as a going concern is a risk factor.
• The company's ability to comply with credit facilities is a risk factor.
• The company's ability to receive remaining proceeds from the sale of its Medicare Advantage business in California in a timely manner is a risk factor.
• The company's ability to obtain short or long term debt or equity financing needed to operate its business is a risk factor.
• The company's ability to quickly and efficiently complete the wind down of its remaining Individual and Family Plan (IFP) and MA businesses, including by satisfying liabilities of those businesses when due and payable is a risk factor.
• Potential disruptions to the business due to the transaction or due to corporate restructuring and any resulting headcount reduction is a risk factor.
• The company's ability to accurately estimate and effectively manage the costs relating to changes in its business offerings and models is a risk factor.
• A delay or inability to withdraw regulated capital from the company's subsidiaries is a risk factor.
• A lack of acceptance or slow adoption of the company's business model is a risk factor.
• The company's ability to retain existing consumers and expand consumer enrollment is a risk factor.
• The company's and its care partners' abilities to obtain and accurately assess, code, and report risk adjustment factor scores is a risk factor.
• The company's ability to contract with care providers and arrange for the provision of quality care is a risk factor.
• The company's ability to obtain claims information timely and accurately is a risk factor.
• The impact of any pandemic or epidemic on the company's business and results of operations is a risk factor.
• The risks associated with the company's reliance on third-party providers to operate its business is a risk factor.
• The impact of modifications or changes to the U.S. health insurance markets is a risk factor.
• The company's ability to manage any growth of its business is a risk factor.
• The company's ability to operate, update or implement its technology platform and other information technology systems is a risk factor.
• The company's ability to retain key executives is a risk factor.
• The company's ability to successfully pursue acquisitions, integrate acquired businesses, and quickly and efficiently divest businesses as needed is a risk factor.
• The occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest is a risk factor.
• The company's ability to prevent and contain data security incidents and the impact of data security incidents on its members, patients, employees and financial results is a risk factor.
• The company's ability to comply with requirements to maintain effective internal controls is a risk factor.
• The company's ability to adapt to mitigate risks associated with its ACO businesses, including any unanticipated market or regulatory developments is a risk factor.

Future Outlook

NeueHealth will become a privately held company with the flexibility and resources to continue advancing its value-driven, consumer-centric care model.

Management Comments

• Mike Mikan, President and CEO of NeueHealth, stated that the transaction places NeueHealth in a strong position for continued growth while maximizing value for all of NeueHealth's public stockholders.
• Mohamad Makhzoumi, Co-CEO of NEA, expressed confidence in the NeueHealth team and their ability to continue to lead the Company, reaffirming NEA's commitment to making high-quality healthcare accessible and affordable.

Industry Context

The acquisition reflects the ongoing trend of private equity firms investing in and taking healthcare companies private to drive value-based care models and improve accessibility and affordability.

Comparison to Industry Standards

• The 70% premium offered to NeueHealth stockholders is a significant premium compared to typical acquisition premiums in the healthcare industry, which often range from 20% to 40%.
• Similar transactions in the healthcare space, such as the acquisition of Change Healthcare by UnitedHealth Group, have faced regulatory scrutiny and required divestitures to gain approval.
• The involvement of NEA, a well-established venture capital firm with a strong track record in healthcare investments, adds credibility to the transaction and suggests a long-term commitment to NeueHealth's vision.

Related Party Transactions

• Certain stockholders of NeueHealth, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company.

Stakeholder Impact

• Shareholders will receive a 70% premium for their shares.
• The executive leadership team will continue in their roles.
• The company will have the flexibility and resources to continue advancing its value-driven, consumer-centric care model.
• The transaction is expected to benefit consumers, providers, and payors through improved healthcare accessibility and affordability.

Next Steps

• The Company will file a proxy statement on Schedule 14A with the SEC.
• The Company and NEA will jointly file a transaction statement on Schedule 13E-3 with the SEC.
• NeueHealth will seek stockholder approval for the merger agreement.
• The Special Committee will solicit and consider alternative acquisition proposals during the go-shop period.
• The parties will work to satisfy customary closing conditions, including receipt of certain regulatory approvals.
• Upon completion of the transaction, NeueHealth's common stock will be de-listed from the NYSE.

Key Dates

Keywords

acquisition, merger, NeueHealth, NEA, private equity, healthcare, value-based care, go-shop, stockholders, regulatory approvals